Skip to main content

Table 1 AZD5363 inhibits proliferation of a subset of GC cell lines in vitro

From: The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

Cell line

Genetic background

 

GI50 (μmol/L)

PIK3CA

PTEN

HGC27

E542K

LOSS

0.445

IM95m

E452K

WT

0.510

AGS

E453K

WT

0.552

NCI-N87

WT

WT

1.037

23132/87

WT

WT

1.671

MKN1

E545K

WT

2.421

SNU-620

WT

WT

3.384

SNU-638

WT

WT

4.523

SNU-1

WT

WT

5.258

SNU-601

WT

WT

5.938

SNU-668

WT

WT

6.003

HS746T

WT

WT

6.084

KATO III

WT

WT

7.267

SNU-484

WT

WT

7.392

SNU-16

WT

WT

11.097

OCUM-1

WT

WT

14.515

NUGC-3

WT

WT

21.873

AZ521

WT

WT

25.448

SNU-216

WT

WT

30.000

NUGC-4

WT

WT

30.000

SNU-5

WT

WT

30.000

GTL-16

WT

WT

30.000

MKN74

WT

WT

30.000

PAMC82

WT

WT

30.000

  1. A panel of GC cell lines with differing genetic backgrounds were screened in a standard MTS cell proliferation assay. The PI3KCA mutation and PTEN expression status were determined by ASPCR and IHC respectively.